![College of Pharmacy Faculty Research and Publications](../../assets/md5images/15f9f0b18dd4c040815af3e6c4efc5f1.jpg)
College of Pharmacy Faculty Research and Publications
Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease
Document Type
Article
Publication Title
The Senior Care Pharmacist
Publication Date
2-1-2024
Volume
39
Issue
2
First Page
75
Last Page
77
Abstract
Lecanemab-irmb (Leqembi™) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease (AD). AD is an irreversible and progressive neurodegenerative disorder affecting more than 6.5 million Americans 65 years of age and older and it is projected to rise to 14 million by 2060. As the disease progresses, it deteriorates short-term memory and thinking skills and, eventually, the ability to perform simple tasks of daily living. The cost of care for AD patients in the United States is estimated at more than $183 billion every year.
Copyright held by
American Society of Consultant Pharmacists
Recommended Citation
Gettman, L. (2024). Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease. The Senior Care Pharmacist, 39 (2), 75-77. http://dx.doi.org/https://doi.org/10.4140/TCP.n.2024.75